Medtronic Reports Strong Q1 Earnings, Raises Full-Year Guidance
Medtronic (NYSE:MDT) reported first-quarter fiscal 2027 results that beat analyst expectations and raised its full-year guidance. The company's adjusted earnings per share came in at $1.45 versus a consensus estimate of $1.39, while revenue rose to $9.8 billion from $9.55 billion expected. Medtronic increased organic revenue growth guidance for fiscal 2027 to between 7.25% and 7.75%, up from the previous range of 6.75% to 7.25%. The company also raised its full-year adjusted EPS forecast, with a midpoint now at $5.97 compared to an analyst estimate of $5.95. Strong performance was driven by growth across multiple business segments, including Cardiovascular (18.9%), Neuroscience (9.3%), and Medical Surgical (10.2%). The company also completed two acquisitions during the quarter—Scientia Vascular and SPR Therapeutics—and noted an additional week in Q1 contributed $570 million to organic revenue growth.
Tickers: $MDT
Topics: financial_performance medical_devices